- Conditions
- Hypertension
- Interventions
- default intensification
- Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hypertension
- Interventions
- Eplerenone, placebo
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 40 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Philadelphia, Pennsylvania
- Conditions
- Cirrhosis, Hepatic Encephalopathy, Ascites, Fatigue
- Interventions
- Not listed
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Unresectable Hepatocellular Carcinoma
- Interventions
- Hepatic artery embolization (HAE), Bumetanide
- Procedure · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 2 more
- Conditions
- Liver Cirrhosis, Acute Kidney Injury, Hepatorenal Syndrome
- Interventions
- Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy
- Combination Product
- Lead sponsor
- Azienda Ospedaliera di Padova
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • New Orleans, Louisiana • Boston, Massachusetts + 2 more
- Conditions
- Heart Defects, Congenital, Cardiopulmonary Bypass
- Interventions
- nesiritide, Placebo
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Up to 1 Year
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease
- Interventions
- Metolazone, Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Palo Alto, California
- Conditions
- End-Stage Kidney Disease
- Interventions
- Hemodialysis twice weekly, Hemodialysis thrice weekly
- Device · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 10
- States / cities
- Jacksonville, Florida • Atlanta, Georgia • Baltimore, Maryland + 7 more
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
- Interventions
- Cordella™ Pulmonary Artery Sensor System
- Device
- Lead sponsor
- Endotronix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 35 more
- Conditions
- End Stage Renal Disease on Dialysis
- Interventions
- Dry weight target adjustment, Anti-hypertensive medications
- Other · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- San Francisco, California • Seattle, Washington
- Conditions
- Delayed Graft Function
- Interventions
- Furosemide, Placebo
- Drug
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Heart Failure
- Interventions
- Torsemide, Standard Outpatient Heart Failure Management
- Drug · Other
- Lead sponsor
- New York City Health and Hospitals Corporation
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Hypertension
- Interventions
- iPSC
- Genetic
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Heart Failure, Heart Diseases, Cardiovascular Diseases
- Interventions
- Usual heart failure care, Interdisciplinary palliative care
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Hypertension
- Interventions
- Intensive control of SBP, Standard control of SBP
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 50 Years and older
- Enrollment
- 9,361 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2019
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Ductus Arteriosus, Patent
- Interventions
- Percutaneous Patent Ductus Arteriosus Closure (PPC), Responsive Management Intervention, Echocardiogram, cardiac
- Device · Combination Product · Diagnostic Test
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 7 Days to 32 Days
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more
- Conditions
- Edema, Hypervolemia, Chronic Kidney Diseases, Nephrotic Syndrome
- Interventions
- Diuretic Tuner
- Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hypertension
- Interventions
- Loop diuretics, thiazides, dihydropyridines, Telmisartan
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 40,048 participants
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Essential Hypertension
- Interventions
- Lisinopril, Amlodipine, Hydrochlorothiazide
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 9 Years to 22 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Nocturia
- Interventions
- fedovapagon 1 mg, fedovapagon 2 mg, fedovapagon 4 mg, Placebo ( sugar pill)
- Drug
- Lead sponsor
- Vantia Ltd
- Industry
- Eligibility
- 55 Years and older · Male only
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 53 more
- Conditions
- Bronchopulmonary Dysplasia, Hyponatremia on Diuretics
- Interventions
- Sodium supplementation, Fluid restriction
- Procedure
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 4 Weeks to 6 Months
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Heart Failure
- Interventions
- Loop Diuretics vs. loop + thiazide diuretics
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Cardiac Failure, Renal Failure, Kidney Failure
- Interventions
- Protocolized Diuretic Strategy
- Drug
- Lead sponsor
- Kelly V. Liang, MD
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Liver Failure
- Interventions
- Vasopressin, Normal saline placebo
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina